[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Women's Hospital School Of Medicine Zhejiang University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":614},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,33,0,25,[9,47,67,91,113,141,164,189,213,237,266,288,311,336,361,389,407,426,442,469,491,515,536,562,585],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100339727","phase-3-study-of-hysteroscopic-repeat-curettage-as-the-first-line-treatment-in-low-risk-postmolar-gestational-trophoblastic-neoplasia-100339727",false,"NCT03703271","Study of Hysteroscopic Repeat Curettage as the First-line Treatment in Low-risk Postmolar Gestational Trophoblastic Neoplasia","A Non-Inferiority Prospective Randomized Multicenter Clinical Control Study of Hysteroscopic Repeat Curettage as the Primal Management of Low-risk Postmolar Gestational Trophoblastic Neoplasia","Inclusion Criteria:\n\n* low-risk postmolar gestational trophoblastic neoplasia (GTN)\n* World Health Organization(WHO) risk score≤4\n* Age≤60 years; female, Chinese women\n* Initial treatment\n* Performance status: Karnofsky score≥60\n* Laboratory tests: WBC≥3.5×10(9)\u002FL, ANC≥1.5×10(9)\u002FL, PLT≥80×10(9)\u002FL, serum bilirubin≤ 1.5 times the upper limit of normal, transaminase≤ 1.5 times the upper limit of normal,blood urea nitrogen, Cr≤ normal\n* Provide written informed consent.\n\nExclusion Criteria:\n\n* Patients with unconfirmed diagnosis of GTN\n* Patients with placental-site trophoblastic tumor (PSTT) or epithelioid trophoblastic tumor (ETT)\n* WHO risk score ≥5分\n* The diameter of a single metastatic lesion in the lung was ≥2cm\n* The number of lung CT metastases was≥ 5\n* With severe or uncontrolled internal disease, unable to receive chemotherapy\n* Concurrently participating in other clinical trials\n* Unable or unwilling to sign informed consents\n* Unable or unwilling to abide by protocol","FEMALE","12 Years","60 Years",{"count":21,"type":22},70,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","Study of hysteroscopic repeat curettage as the first-line treatment in low-risk postmolar gestational trophoblastic neoplasia compared with the MTX single drug chemotherapy",[28],"Gestational Trophoblastic Neoplasia",[30,28,31,32,33],"postmolar","hysteroscopic","repeat curettage","methotrexate","RECRUITING","2026-06-28",{"date":37,"type":38},"2026-07-01","ACTUAL",{"date":40,"type":38},"2019-03-01",{"date":42,"type":22},"2026-12-31",{"name":44,"class":45},"Women's Hospital School Of Medicine Zhejiang University","OTHER",1,{"id":48,"slug":49,"hasResults":12,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":66,"locationsCount":46},"100641675","the-treatment-outcomes-of-cesarean-scar-pregnancy-100641675","NCT07608094","The Treatment Outcomes of Cesarean Scar Pregnancy","Inclusion Criteria:\n\n1. Women over 18 years old with a history of cesarean section\n2. Ultrasound diagnosis of cesarean scar pregnancy\n3. No severe internal or external diseases, such as liver disease, kidney disease, cardiovascular disease, cerebrovascular disease, etc., and able to tolerate surgery\n\nExclusion Criteria:\n\n1. Women under the age of 18\n2. CSP patients who have received treatment in other hospitals","18 Years",{"count":55,"type":22},82,"OBSERVATIONAL","A prospective randomized controlled study evaluating the impact of various treatment modalities for cesarean scar pregnancy on treatment outcomes and pregnancy outcomes",[59],"Cesarean Scar Pregnancy","2026-06-16",{"date":62,"type":38},"2026-06-22",{"date":64,"type":38},"2025-08-13",{"date":42,"type":22},{"name":44,"class":45},{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":17,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":89,"locationsCount":90},"100521279","a-multicenter-observational-study-on-the-development-and-health-effects-of-premature-ovarian-insufficiency-100521279","NCT06067529","A Multicenter Observational Study on the Development and Health Effects of Premature Ovarian Insufficiency","POI","Women with POI\n\n1. Inclusion Criteria 1.1 Age at Diagnosis: Less than 40 years of age. 1.2 Diagnosis of POI: Met one of the following diagnostic criteria based on ESHRE guidelines: Spontaneous POI: Oligomenorrhea or amenorrhea for at least 4 months, combined with elevated FSH levels (\\> 25 IU\u002FL) on two occasions at least 4 weeks apart.\n\n   Iatrogenic POI: Documented history of bilateral oophorectomy, or ovarian failure resulting from chemotherapy or radiotherapy.\n\n   1.3 Informed Consent: Willing to participate in the study, provide biological samples, and complete long-term follow-up assessments.\n2. Exclusion Criteria 2.1 Current Pregnancy or Lactation: Women who were pregnant or breastfeeding at the time of enrollment.\n\n2.2 Severe Systemic Conditions: Presence of severe somatic or psychiatric diseases (e.g., active malignancy not related to POI, severe heart\u002Frenal failure, or cognitive impairment) that would preclude adherence to the study protocol or long-term follow-up.\n\nControl\n\n1. Inclusion Criteria:\n\n   1.1 Age: 18-50 years. 1.2 Menstrual History: Regular menstrual cycles (21-35 days) for the past 12 months.\n\n   1.3 Consent: Willingness to participate, provide biological samples, and provide written informed consent.\n2. Exclusion Criteria:\n\n2.1 Physiological Status: Pregnancy, breastfeeding, or clinical perimenopause\u002Fpostmenopause.\n\n2.2 Reproductive Disorders: History of PCOS, endometriosis, or other reproductive pathologies.\n\n2.3 Iatrogenic \\& Toxic Factors: Prior ovarian surgery (e.g., cystectomy), chemotherapy, or radiotherapy.\n\n2.4 Systemic Diseases: History of endocrine (e.g., thyroid dysfunction), autoimmune, cardiovascular, liver, kidney, or hematological diseases, or malignancy.\n\n2.5 Genetic \\& Familial Background: First-degree relatives with POI or early menopause (\\\u003C 45 years). Family history of hereditary diseases. 2.6 Medication: Use of hormonal drugs or contraceptives within the last 6 months.\n\nOvarian Surgery group\n\n1. Inclusion Criteria:\n\n   1.1 Age: 18-60 years. 1.2 Patients with ovarian surgery: women scheduled to undergo ovarian surgery for gynecological disease.\n\n   1.3 Informed Consent: Willing to participate in the study, provide biological samples, and sign the informed consent.\n2. Exclusion Criteria:\n\n2.1 Reproductive Disorders: History of PCOS, endometriosis, or other reproductive pathologies.\n\n2.2 Medication: Use of hormonal drugs or contraceptives within the last 6 months.\n\n2.3 Genetic or chromosomal abnormalities: Turner syndrome, or other genetic disease.\n\n2.4 Physiological Status: Pregnancy, breastfeeding, or seeking the help of assisted reproductive technology.\n\n2.5 Severe systemic Diseases: History of endocrine (e.g., thyroid dysfunction), autoimmune, cardiovascular, liver, kidney, hematological diseases, malignancy, or cognitive impairment.\n\nOophorectomy group\n\n1. Inclusion Criteria:\n\n   1.1 Age: 45-65 years. 1.2 Patients with oophorectomy: women scheduled to undergo oophorectomy due to gynecological diseases and met criteria for being menopausal.\n\n   1.3 Menopausal status: at least 12 consecutive months of amenorrhea without other medical causes.\n\n   1.3 Informed Consent: Willing to participate in the study, provide biological samples, and sign the informed consent.\n2. Exclusion Criteria:\n\n2.1 Reproductive Disorders: History of PCOS, endometriosis, or other reproductive pathologies.\n\n2.2 Medication: Use of hormonal drugs or contraceptives within the last 6 months.\n\n2.3 Genetic or chromosomal abnormalities: Turner syndrome, or other genetic disease 2.4 Physiological Status: Pregnancy, breastfeeding, or seeking the help of assisted reproductive technology.\n\n2.5 Severe systemic Diseases: History of endocrine (e.g., thyroid dysfunction), autoimmune, cardiovascular, liver, kidney, hematological diseases, malignancy, or cognitive impairment.",true,"10 Years","65 Years",{"count":78,"type":22},1080,"Premature ovarian insufficiency (POI) refers to the occurrence of ovarian hypofunction in women before the age of 40, which seriously affects women's overall health and quality of life. However, there is currently insufficient understanding of the risk factors, pathogenesis, short-term and long-term health effects of POI, and the health effects of the disease, and there is a lack of high-quality evidence to support clinical diagnosis and treatment decisions. This study intends to construct a hospital-based multi-center POI case-control and prospective special disease cohort, after baseline assessment and follow-up monitoring, collect disease characteristics, lifestyle, social psychology, environmental and occupational exposure, biological samples and other data, aiming to observe POI The natural occurrence, progression and health impact of POI, clarify the risk factors of POI, evaluate the impact of POI on women's health and disease risk, and discuss the benefits, risks and options of HRT for POI patients. The results of this study will deepen and expand the understanding of the occurrence and development of POI and its short-term and long-term health effects, provide high-level evidence for optimizing POI prevention, diagnosis and treatment strategies, and establish a long-term management system, laying the foundation for interventional research.",[81],"Premature Ovarian Insufficiency",[81],"2026-05-25",{"date":85,"type":38},"2026-05-28",{"date":87,"type":38},"2023-10-10",{"date":42,"type":22},{"name":44,"class":45},2,{"id":92,"slug":93,"hasResults":12,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":4,"eligibilityCriteria":97,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},"100640499","utility-of-whole-genome-sequencing-in-fetuses-with-abnormal-ultrasound-findings-100640499","NCT07606989","Utility of Whole Genome Sequencing in Fetuses With Abnormal Ultrasound Findings","Clinical Study on Prenatal Diagnosis of Fetal Abnormalities of Unknown Cause Using Whole-Genome Sequencing: A Multicenter Study","Inclusion Criteria:\n\n1. Pregnant women aged ≥ 18 years.\n2. Singleton pregnancy.\n3. Gestational age between 11+0 and 32+0 weeks, with ultrasound or MRI indicating a definite structural malformation in the fetus (may be with or without soft marker abnormalities) requiring prenatal diagnosis (see Appendices 1 and 2). Fetal developmental abnormalities include those of the central nervous system, cardiovascular system, craniofacial\u002Fneck region, chest\u002Fmediastinum, abdomen\u002Fdigestive tract, urinary system, skeletal system\u002Flimbs, and systemic abnormalities such as fetal hydrops, abnormally thickened placenta with hydrops, and severe growth restriction. Criteria for ultrasound soft markers and structural malformations are provided in the appendices.\n4. Planned to undergo at least one invasive or postnatal procedure for genetic diagnosis, and consent to the use of residual diagnostic samples for research testing.\n5. Signed unified informed consent form, agreement to follow-up, and consent for storage and submission of samples and data according to the protocol.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years or individuals lacking full capacity for civil conduct.\n2. Twin or multiple pregnancies.\n3. Known parental or familial carrier status of a pathogenic variant highly consistent with the current fetal phenotype, where testing is planned only for targeted confirmation.\n4. Refusal to consent to the storage and use of samples and data for this study.\n5. Other conditions deemed unsuitable for participation in this study by the investigator.",{"count":99,"type":22},1000,"The goal of this observational study is to learn if whole-genome sequencing (WGS) can help find the genetic cause in fetuses with structural abnormalities that remain unexplained after standard genetic testing (such as karyotyping, chromosomal microarray, or whole-exome sequencing). It will also learn how WGS results may affect pregnancy management and family decision-making.\n\nThe main questions it aims to answer are:\n\nHow often does WGS identify a genetic cause in these fetuses? Does WGS find more genetic causes compared to standard genetic tests? Can combining WGS with other molecular analyses help discover new disease genes or pathways? Researchers will compare WGS results to results from standard genetic tests to see if WGS finds more genetic causes.\n\nParticipants are pregnant women whose fetuses have structural abnormalities seen on ultrasound or MRI, with negative results from routine genetic testing. Participants will:\n\nUndergo an invasive procedure (such as amniocentesis) or provide postnatal samples as part of their regular medical care Allow the use of leftover samples for WGS and additional molecular studies Be followed until after delivery to collect information on pregnancy outcomes and neonatal health",[102,103],"Prenatal Diagnosis","Fetal Diseases","2026-05-20",{"date":106,"type":38},"2026-05-26",{"date":108,"type":38},"2026-03-12",{"date":110,"type":22},"2028-03-12",{"name":44,"class":45},4,{"id":114,"slug":115,"hasResults":12,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":12,"sex":17,"minAge":120,"maxAge":76,"enrollmentInfo":121,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":123,"conditions":124,"keywords":127,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":4},"100640087","peripheral-blood-cytof-immune-model-for-cervical-lesion-detection-in-hpv1618-women-100640087","NCT07606677","Peripheral Blood CyTOF Immune Model for Cervical Lesion Detection in HPV16\u002F18+ Women","Mass Cytometry-based Peripheral Blood Immune Model for Accurate Detection of Cervical Lesions in HPV16\u002F18-positive Women: a Multicenter Study","Inclusion Criteria:\n\n* Availability of cervical cytology results\n* Consent to colposcopy and cervical biopsy\n* Signed informed consent\n\nExclusion Criteria:\n\n* Confirmed diagnosis of CIN2 or worse\n* Prior cervical ablation, cervical conization, chemoradiotherapy, or immunotherapy\n* Other malignancy within the past 2 years not in complete remission\n* Presence of other systemic immune disease or active infection\n* Pregnancy or lactation\n* Inability to comply with follow-up and examinations\n* Inability to comply with study procedures, restrictions, and requirements, as determined by the investigator","25 Years",{"count":122,"type":22},1465,"This prospective, multicenter cohort study will recruit eligible HPV16\u002F18-positive women from three tertiary hospitals in China. Peripheral blood samples and clinical data (cytology, HPV genotyping, colposcopy-directed biopsy) will be collected, followed by standardized mass cytometry (CyTOF) to develop and evaluate an immune model across cervical lesion grades.",[125,126],"CIN 2\u002F3","Cervical Cancer (Early Detection)",[128,129,130,131,132],"cervical cancer","Cervical Intraepithelial Neoplasia","HPV16\u002F18","Mass cytometry","Immune model","NOT_YET_RECRUITING","2026-05-18",{"date":106,"type":38},{"date":137,"type":22},"2026-05-15",{"date":139,"type":22},"2028-03-31",{"name":44,"class":45},{"id":142,"slug":143,"hasResults":12,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":74,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":23,"phases":151,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":46},"100599287","a-rct-of-labor-induction-at-39-weeks-in-low---risk-women-in-china-100599287","NCT07082530","A RCT of Labor Induction at 39 Weeks in Low - Risk Women in China","Labor Induction in Low-risk Women at 39 Weeks of Gestation: A Randomized Trial in China","LIRIC","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Singleton pregnancy or twin pregnancy reduced to singleton before 14 weeks.\n3. Gestational age between 38 weeks 4 days or 38 weeks 6 days at randomization.\n4. Eligible for vaginal delivery with a desire for vaginal birth.\n5. Reliable gestational age determination.\n6. Maternal and fetal conditions assessed as low-risk by at least two senior obstetricians, with no indications requiring delivery before 41 weeks.\n7. Ability to understand study information and provide informed consent.\n\nExclusion Criteria:\n\n1. First-trimester ultrasound estimate \\>13 weeks 6 days.\n2. Planned induction before 41 weeks.\n3. Planned cesarean delivery or contraindications to vaginal delivery.\n4. Already delivered, in labor, or ruptured membranes at enrollment.\n5. Placenta previa, vasa previa, placenta accreta, or placental abruption.\n6. Contraindications to induction (e.g., cervical cancer, history of uterine rupture, genital tract malformations, abnormal fetal position, cord prolapse).\n7. Active vaginal bleeding exceeding spotting.\n8. History of cesarean delivery or uterine\u002Fcervical surgery.\n9. Cervical cerclage during this pregnancy.\n10. Maternal conditions not suitable for expectant management beyond 39 weeks (e.g., pregestational diabetes, gestational diabetes requiring insulin, hypertensive disorders, intrahepatic cholestasis of pregnancy).\n11. Fetal conditions not suitable for expectant management beyond 39 weeks (e.g., fetal death, major anomalies, growth restriction, macrosomia, anemia, oligohydramnios, polyhydramnios).\n12. Maternal infections or positive screenings for sexually transmitted pathogens or group B Streptococcus.\n13. Planned delivery at a non-study facility.\n14. Participation in another intervention study affecting delivery management.",{"count":150,"type":22},1074,[152],"NA","The investigators are committed to identifying the optimal timing of delivery for low-risk pregnancies. While current guidelines typically recommend induction at 41 weeks, emerging evidence suggests that elective induction at 39 weeks may lead to improved maternal and neonatal outcomes. The U.S.-based ARRIVE trial demonstrated that induction at 39 weeks significantly reduced cesarean delivery rates compared to expectant management, and a similar randomized controlled trial (French-ARRIVE) is ongoing in France. However, population-specific evidence for the Chinese population remains lacking.\n\nThis study is designed to establish a prospective cohort of low-risk pregnant women in China, comparing the effects of induction at 39 weeks, induction at 41 weeks, and expectant management on cesarean section rates and other maternal and neonatal outcomes. In addition, multi-omics technologies will be employed to analyze cord blood samples-including metabolomics and proteomics-to identify early biomarkers potentially associated with long-term child health. The study will begin with a pilot phase to assess feasibility and inform operational strategies for large-scale implementation.\n\nThe ultimate goal of this project is to generate evidence tailored to the Chinese population to support more individualized decision-making, improve clinical outcomes, and enhance maternal and neonatal safety.",[155],"Cesarean Delivery","2026-05-14",{"date":158,"type":38},"2026-05-19",{"date":160,"type":38},"2025-07-30",{"date":162,"type":22},"2027-06-30",{"name":44,"class":45},{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":19,"enrollmentInfo":171,"targetDuration":4,"studyType":23,"phases":173,"briefSummary":174,"conditions":175,"keywords":177,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":46},"100346042","study-of-different-therapeutic-strategies-in-hydatidiform-mole-with-lung-nodule-100346042","NCT03785574","Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule","Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule，A Prospective Multicentre Randomized Controlled Trial","Inclusion criteria\n\nEligible patients have to meet all of the following criteria:\n\n1. Pathologically confirmed HM.\n2. The lung nodules are detected by lung CT and metastatic lesions could not be excluded (before or after the suction dilation and curettage).\n3. The hCG level does not meet FIGO diagnostic criteria (2018) of GTN.\n4. The patients are willing to compliant with the study protocol and be followed up at regular intervals.\n5. The patients agree to sign an informed consent form.\n\nExclusion criteria\n\n1. The patients with a previous history of lung nodules.\n2. The imaging impression of lung nodules suggested definitely caused by other diseases, such as tuberculosis, pneumonia, etc.\n3. The patients have undergone prophylactic hysterectomy or chemotherapy.\n4. Pathologically confirmed gestational trophoblastic neoplasia before and at enrollment.\n5. Patients have immunosuppressive diseases or take immunosuppressants.\n6. Patients are participating in other clinical trials at same time.\n7. Patients were unable or unwilling to provide written informed consent.",{"count":172,"type":22},30,[152],"The purpose of present study is to provide clinical evidences for the appropriate management of molar pregnancy with lung nodule. The hydatidiform mole patients with lung nodule ≥1.0cm will be randomized into 2 groups: A. treated with chemotherapy immediately, B. follow up until hCG level met FIGO diagnostic criteria of GTN (B1) or hCG level declined to normal spontaneously (B2). Lung nodule \\\u003C1.0cm will directly treated as group C",[176,28],"Hydatidiform Mole",[178,179,180],"Pulmonary Nodule","Chemotherapy","Chorionic Gonadotrophin","2026-03-13",{"date":183,"type":38},"2026-03-16",{"date":185,"type":38},"2018-12-24",{"date":187,"type":22},"2030-09-01",{"name":44,"class":45},{"id":190,"slug":191,"hasResults":12,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":197,"targetDuration":4,"studyType":23,"phases":198,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":205,"lastUpdatePostDateStruct":206,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":4},"100621389","phase-2-immunotherapy-for-surgery-avoidance-in-vulnerable-dmmr-endometrial-cancer-100621389","NCT07369986","Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer","A Phase 2b, Open-Label Study of Iparomlimab and Tuvonralimab to Facilitate Surgery Avoidance in Women With Resectable, Mismatch Repair-Deficient Endometrial Cancer","IMMUNE-SAVE","Inclusion Criteria:\n\n1. Age:18 years or older.\n2. Histologically confirmed endometrial cancer (excluding carcinosarcoma).\n3. FIGO (2009) stage I to IIIC2 disease that is considered surgically completely resectable.\n\nConfirmed dMMR or MSI-H, defined by either loss of expression of one or more mismatch repair proteins (MLH1, PMS2, MSH2, MSH6 or MSI-H) for by immunohistochemistry, or MSI-H status confirmed by polymerase chain reaction assay.\n\n5)No prior systemic anti-tumor therapy (including chemotherapy, radiotherapy, targeted therapy, or immunotherapy) within the past 5 years.\n\n6)Eastern Cooperative Oncology Group Performance Status of 0 or 1. 7)Laboratory test results within 7 days prior to the first dose must meet the following criteria. Laboratory values are not valid if the patient received granulocyte colony-stimulating factor or a blood transfusion within 14 days prior to sample collection.\n\nWhite blood cell count ≥2,000\u002Fmm3 and absolute neutrophil count ≥1,500\u002Fmm3. Platelet count ≥100,000\u002Fmm3. Hemoglobin ≥9.0 g\u002FdL.\n\nAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0-fold of the upper limit of normal (ULN) (or ≤5.0-fold the ULN of the study site in patients with liver metastases). Total bilirubin ≤1.5-fold of the ULN.\n\nCreatinine ≤1.5-fold of the ULN or creatinine clearance (either the measured or estimated value using the Cockcroft-Gault equation) ≥ 45 mL\u002Fmin.\n\n8)Women of childbearing potential:\n\n* Must agree to use contraception from the time of informed consent until at least 5 months after the last dose of the investigational product.\n* Must agree not to breastfeed from the time of informed consent until at least 5 months after the last dose.\n\nExclusion Criteria:\n\n1)Multiple primary malignancies, except for: adequately resected basal cell or squamous cell carcinoma of the skin (Stage I), superficial bladder cancer, or any other malignancy that has been disease-free for over 5 years.\n\nHistory of severe hypersensitivity to any monoclonal antibody. 3)Known hypersensitivity to iparomlimab and tuvonralimab or any of their excipients.\n\n4)Concurrent or history of clinically significant autoimmune disease. 5)Current or prior interstitial lung disease or pulmonary fibrosis documented by imaging or clinical assessment. Patients with radiation pneumonitis may be enrolled if it is confirmed to be stable (beyond the acute phase) and without anticipated recurrence.\n\n6)Concurrent diverticulitis or symptomatic gastrointestinal ulcerative disease. 7)Symptomatic pericardial effusion, pleural effusion, or ascites requiring treatment.\n\n8)Uncontrolled tumor-related pain. 9)Transient ischemic attack, cerebrovascular accident, or thromboembolism within 180 days prior to enrollment.\n\n10)Uncontrolled or clinically significant cardiovascular disease, defined as any of the following within 180 days prior to enrollment:\n\n* Myocardial infarction;\n* Unstable angina pectoris;\n* Congestive heart failure of New York Heart Association (NYHA) Class III or IV\n* Poorly controlled hypertension despite appropriate treatment (e.g., sustained systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥90 mmHg for ≥ 24 hours)\n* Arrhythmia requiring treatment 11)Requirement for ongoing therapeutic anticoagulation (low-dose aspirin or other antiplatelet therapy is permitted).\n\n  12)Poorly controlled diabetes mellitus. 13)Active systemic infection requiring treatment. Systemic corticosteroid therapy (except for temporary use, e.g., for examination or prophylaxis of allergic reactions) or immunosuppressants within 28 days before enrollment.\n\n  15)Patients who have received antineoplastic drugs (e.g., chemotherapy agents, molecular targeted therapy agents, or immunotherapy agents) within 28 days before randomization.\n\n  16)Surgical pleurodesis or pericardium within 28 days prior to enrollment. 17)Major surgery within 4 weeks or minor surgery within 7 days before the first dose, without full recovery. Patients scheduled for major surgery during the study period are excluded (video-assisted thoracoscopic surgery or diagnostic procedures are not considered exclusions if recovery is adequate).\n\n  18)Administration of any therapeutic radiopharmaceutical within 56 days prior to enrollment (diagnostic use is permitted).\n\n  19)Active tuberculosis. 20)Positive serology for human immunodeficiency virus (HIV-1\u002F2 antibody), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) antibody. Patients who are HBsAg-positive may be enrolled if hepatitis B virus DNA is below the lower limit of detection.\n\n  21)Any other severe medical or psychiatric condition, or abnormal laboratory findings, that in the investigator's judgment would increase the risk of study participation, compromise protocol compliance, or interfere with the interpretation of study results.\n\n  22)Participation in another clinical trial and receipt of an investigational product within 4 weeks prior to the first dose.\n\n  23)Pregnancy, lactation, or intention to become pregnant during the study period.\n\n  24)Positive urine pregnancy test within 72 hours before treatment initiation (if urine test is positive or indeterminate, a confirmatory serum pregnancy test is required).",{"count":172,"type":22},[199],"PHASE2","Efficacy evaluate of iparomlimab and tuvonralimab (a PD-1\u002FCTLA-4 bispecific antibody) in patients with surgically resectable dMMR endometrial cancer.",[202,203,204],"Endometrial Cancer","Immunotherapy","Mismatch Repair Deficiency","2026-01-18",{"date":207,"type":38},"2026-01-27",{"date":209,"type":22},"2026-03-01",{"date":211,"type":22},"2028-12-31",{"name":44,"class":45},{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":74,"sex":220,"minAge":4,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":223,"conditions":224,"keywords":226,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":46},"100621025","accurate-assessment-and-intervention-research-on-newborn-whole-genome-sequencing-and-genetic-disease-risk-100621025","NCT07365254","Accurate Assessment and Intervention Research on Newborn Whole Genome Sequencing and Genetic Disease Risk","Accurate Assessment and Intervention Research on Newborn Whole Genome Sequencing and Genetic Disease Risk(China Baby Omics)","Inclusion Criteria:\n\n* Families with ongoing pregnancies (via assisted reproductive therap or natural conception) and newborn infants.\n\nExclusion Criteria:\n\n* None","ALL",{"count":222,"type":22},1000000,"Maternal and infant health is the foundation of public health, and its status directly reflects the overall health level of the population. With rapid socioeconomic development and increasingly severe environmental issues, health problems among women and children have become more widespread and diverse. In the new era, maternal and child health faces new challenges, with higher demands in areas such as reproductive health promotion, birth defect prevention, maternal and infant safety, and childhood disease prevention. Cohort studies, as an epidemiological research method for exploring disease etiology, involve recruiting participants before or during pregnancy and conducting follow-ups on pregnancy, childbirth, and maternal and child health outcomes after birth to identify various factors influencing diseases and health. Focusing on the early stages of life, this approach is an effective method for studying the associations between environmental, genetic, and behavioral risk factors during early life and embryonic development, fetal health, and infant health.\n\nThis project plans to conduct long-term follow-ups on couples and their offspring on a family basis, while collecting biological samples at multiple time points. A systematic multi-dimensional assessment, based on clinical information and multi-omics data from the enrolled population, will be used to infer the causes of reproductive and pregnancy-related diseases and developmental abnormalities, identify new biomarkers for pregnancy-related diseases, establish predictive models, and recognize risk factors in the early life of offspring, thereby providing guidance for the prevention and control of reproductive and developmental diseases.",[225],"Genetic Disease",[227,228],"Newborn","Multiomics","2026-01-15",{"date":231,"type":38},"2026-01-26",{"date":233,"type":38},"2025-02-14",{"date":235,"type":22},"2030-12-31",{"name":44,"class":45},{"id":238,"slug":239,"hasResults":12,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":12,"sex":220,"minAge":245,"maxAge":246,"enrollmentInfo":247,"targetDuration":4,"studyType":23,"phases":249,"briefSummary":251,"conditions":252,"keywords":254,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":259,"startDateStruct":261,"completionDateStruct":263,"leadSponsor":265,"locationsCount":46},"100580092","early-phase-1-modified-diagnosis-and-treatment-of-neonatal-hemolysis-with-etcoc-in-snh-100580092","NCT06832800","Modified Diagnosis and Treatment of Neonatal Hemolysis With ETCOc in sNH","Modified Diagnosis and Treatment of Neonatal Hemolysis Incorporated With ETCOc Measurement in Severe Neonatal Hyperbilirubinemia Management","MDTinsNH","Inclusion Criteria: Inclusion Criteria:\n\nInfants with gestational age of 35(+0) to 41(+6) weeks and birth weight ≥ 2500 grams\n\n* Infants with severe neonatal hyperbilirubinemia, including those whose serum total\n* bilirubin (TSB) levels reach above 20 mg\u002FdL or whose TSB levels at any time reach within 2 mg\u002FdL of the exchange transfusion threshold (i.e., TSB \\> (threshold - 2) mg\u002FdL).\n\nExclusion Criteria:\n\n* Infants with definite congenital genetic metabolic diseases, chromosomal or genetic disorders, or severe malformations.","4 Hours","28 Days",{"count":248,"type":22},250,[250],"EARLY_PHASE1","The goal of this clinical trial is to learn if modified diagnosis and treatment (MDT) of neonatal hemolysis (a common cause to newborn jaundice) incorporated with ETCOc measurement (a non-invasive measurement of exhaled gas) works to prevent brain damage in newborns with severe hyperbilirubinemia (sNH). It will also learn about the. occurrence of cranial MRI in the study participants. The main questions it aims to answer are:\n\n* Does MDT lower the possibilities participants have brain damage before the age of one?\n* How many times of abnormalities in cranial MRI is detected before the age of one? Researchers will compare MDT to a control (a current management) to see if MDT works to prevent brain damage in newborns with sHN.\n\nParticipants will:\n\n* Take MDT or a control method in the management of sNH\n* Assess if there's brain damage before discharge and at the year of one\n* Record how many times of abnormalities in cranial MRI is detected before the age of one",[253],"Neonatal Hyperbilirubinemia",[255,256,257,258],"ETCOc","neonatal hemolysis","neonatal hyperbilirubinemia","modified",{"date":260,"type":38},"2026-01-20",{"date":262,"type":38},"2025-07-21",{"date":264,"type":22},"2027-12-31",{"name":44,"class":45},{"id":267,"slug":268,"hasResults":12,"nctId":269,"briefTitle":270,"officialTitle":271,"acronym":4,"eligibilityCriteria":272,"healthyVolunteers":12,"sex":17,"minAge":273,"maxAge":274,"enrollmentInfo":275,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":277,"conditions":278,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":280,"lastUpdatePostDateStruct":281,"startDateStruct":283,"completionDateStruct":285,"leadSponsor":286,"locationsCount":287},"100498886","association-of-gestational-cardiovascular-health-with-pregnancy-outcomes-100498886","NCT05776082","Association of Gestational Cardiovascular Health With Pregnancy Outcomes","Association of Cardiovascular Health During Pregnancy With Perinatal Outcomes---a Birth Cohort Study","Inclusion Criteria:\n\n* Maternal age: 20-49 years;\n* Natural conception;\n* Single pregnancy;\n* Plan to have routine prenatal examinations and give birth in the research center;\n\nExclusion Criteria:\n\n* Have diseases that affect metabolic function or even threaten the life of the mother and fetus before pregnancy;\n* Assisted reproduction;\n* Multiple pregnancy;\n* Fetus has a known deformity or genetic defects;\n* Incomplete clinical data.","20 Years","49 Years",{"count":276,"type":22},5000,"Pregnancy is a critical period for cardiovascular health risk assessment and interventions to reduce the incidence of cardiovascular disease in both mother and child generations. Recently, the American Heart Association proposed the latest cardiovascular health assessment indicator \"Life's Essential 8\". However, there is still a lack of application data for pregnant women. This project intends to explore the application potential of Life's Essential 8 in cardiovascular health assessment of pregnant women and establish appropriate gestaional cardiovascular health standards.",[279],"Pregnant Women","2025-12-21",{"date":282,"type":38},"2025-12-29",{"date":284,"type":38},"2023-03-01",{"date":264,"type":22},{"name":44,"class":45},3,{"id":289,"slug":290,"hasResults":12,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":4,"eligibilityCriteria":294,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":295,"enrollmentInfo":296,"targetDuration":4,"studyType":23,"phases":298,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":308,"leadSponsor":310,"locationsCount":46},"100605795","phase-2-chemo-immunotherapy-for-cervical-cancer-stage-iiicp-trial-100605795","NCT07167160","Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial","Camrelizumab Combined With Chemotherapy for Adjuvant Treatment of Cervical Cancer Patients With Pathologically Confirmed Lymph Node Positivity After Stage Surgery: A Prospective, Single-Arm, Multicenter, Phase II Clinical Trial","Inclusion Criteria:\n\n1. Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery;\n2. Positive PD-L1 expression;\n3. ECOG score ≤1\n\nExclusion Criteria:\n\n1. Positive parametrium or surgical margin;\n2. Incomplete radical surgery;\n3. Residual target lesions;\n4. Active autoimmune disease or autoimmune disease requiring systemic treatment;\n5. Previous treatment with immune checkpoint inhibitors.","70 Years",{"count":297,"type":22},59,[199],"Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.",[301,302],"Cervical Cancer","Immunochemotherapy","2025-12-10",{"date":305,"type":38},"2025-12-18",{"date":307,"type":38},"2025-03-10",{"date":309,"type":22},"2029-12-31",{"name":44,"class":45},{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":4,"eligibilityCriteria":317,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":318,"enrollmentInfo":319,"targetDuration":4,"studyType":23,"phases":321,"briefSummary":322,"conditions":323,"keywords":325,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":46},"100559221","phase-2-clinical-efficacy-study-of-pd-1-inhibitor-combined-with-neoadjuvant-chemotherapy-in-advanced-endometrial-cancer-100559221","NCT06561308","Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer","A Single-arm, Multicenter Phase II Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer in Clinical Efficacy","Inclusion Criteria:\n\n1. Endometrial cancer initially diagnosed as stage III non-operable resectable, stage IV (FIGO, 2009 criteria) after imaging evaluation\n2. Pathologically confirmed endometrial cancer that looks like endometrial carcinoma\n3. Patient age ≥18 years and ≤75 years old\n4. ECOG status score of 0-1\n5. tolerate surgery and radiotherapy\n6. Laboratory tests: WBC ≥3.5×109\u002FL, NEU ≥1.5×109\u002FL, PLT ≥80×109\u002FL, serum ≥80×109\u002FL, serum ≥80×109\u002FL, serum ≥80×109\u002FL, serum ≥80×109\u002FL.\n\n   ×109\u002FL, serum bilirubin ≤1.5 times the high limit of normal value, transaminase ≤1.5 times the high limit of normal value, BUN ≤1.5 times the high limit of normal value.\n\n   1.5 times of the high limit of normal value, BUN, Cr≤normal value;\n7. Able to follow up and good compliance;\n8. Able to sign the informed consent form, including compliance with the requirements and restrictions listed in the informed consent form and the program.\n\nExclusion Criteria:\n\n1. Subjects with an active, known, or suspected autoimmune disease, or a history of an autoimmune disease, except for: vitiligo, alopecia areata, Graves' disease, psoriasis, or eczema that has not required systemic therapy within the last 2 years, hypothyroidism that is asymptomatic or requires only stable doses of hormone replacement therapy (due to autoimmune thyroiditis), type 1 diabetes that requires only stable doses of insulin replacement therapy, asthma that subsides completely in childhood and does not require intervention in adulthood, or diseases that do not recur in the absence of external triggers;\n2. Prior treatment with immune checkpoint inhibitors, including, but not limited to, other anti-PD-1, anti-PD-L1 antibodies, CTLA-4 antibodies, or any treatment directed against immune co-stimulators (e.g., antibodies directed against ICOS, CD40, CD137, GITR, OX40 targets, etc.) that target any mechanism of immune action against tumors;\n3. Known hypersensitivity to any component and\u002For any excipient of the trial regimen;\n4. Immunosuppressive drugs or systemic corticosteroids for immunosuppression (\\>10 mg\u002Fday of prednisone or other equivalent) within 2 weeks prior to trial dosing; topical, ophthalmic, intra-articular, intranasal, and inhaled corticosteroids are permitted;\n5. Received herbs with antitumor effects or drugs with immunomodulatory effects (e.g., thymidine, interferon, interleukin-2) within 2 weeks prior to the trial;\n6. Active systemic infection requiring systemic treatment;\n7. Serious infection within 4 weeks prior to the first dose, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia;\n8. Patients with untreated chronic hepatitis B, or HBV carriers with chronic hepatitis B virus (HBV) DNA greater than 1,000 IU\u002FmL, or patients with active hepatitis C. Inactive HBsAg carriers, treated hepatitis B patients with stable disease (HBV DNA \\\u003C 1000 IU\u002FmL), and cured hepatitis C patients will be eligible for enrollment. HCV antibody-positive subjects will be eligible for the study only if they have a negative HCV RNA test;\n9. Known active tuberculosis (TB), patients with suspected active TB should undergo chest X-ray and sputum examination in conjunction with clinical signs and symptoms for exclusion;\n10. Immunodeficiency or human immunodeficiency virus (HIV antibody positive);\n11. Subjects with active inflammatory bowel disease or a history of such disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea). Subjects who are unable to swallow or who have malabsorption syndrome, uncontrolled nausea, vomiting, diarrhea, or other gastrointestinal disorders that severely interfere with drug intake and absorption;\n12. Known interstitial lung disease that is symptomatic or may interfere with detection or treatment of immune-associated pneumonia;\n13. Treatment with a live or attenuated vaccine administered within 4 weeks prior to the first trial dose, inactivated seasonal influenza virus vaccine is permitted;\n14. Patients who have received a prior allogeneic bone marrow transplant or solid organ transplant;\n15. History of primary malignant tumor within the last 5 years;\n16. Subjects who have undergone major surgery (e.g., open abdomen, open chest, organ resection, etc.) and severe trauma within 28 days prior to the first dose of implantable infusion devices are permitted;\n17. Subjects with a history of gastrointestinal perforation, gastrointestinal fistula, or female genital fistula;\n18. Uncontrolled other co-morbidities, symptoms, or medical history, including: (1) Persons with one of the following cardiovascular diseases or cardiovascular risk factors: myocardial infarction, unstable angina pectoris, pulmonary embolism, acute\u002Fcontinuous myocardial ischemia, cerebral vascular accident, transient ischemic attack, theor other clinically significant\u002Frequired drug intervention arterial or venous thrombosis, embolism or cerebral ischemic events; symptoms of congestive heart failure (NYHA class III or higher) within 6 months (ii) clinically significant bleeding symptoms or a history of significant bleeding characteristics, such as gastrointestinal bleeding, gastric ulcer bleeding, or vasculitis, within 1 month prior to the first dose; (iii) clinically active hemoptysis, active diverticulitis, abdominal abscess, and gastrointestinal obstruction; (iv) uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage; (v) abnormalities of hepatic or renal development, or a history of surgery;\n19. Female patients who are pregnant or breastfeeding; women of childbearing age who refuse to accept contraceptive measures during neoadjuvant immunotherapy;\n20. Concurrent participation in other interventional clinical trials; participation in observational and non-interventional clinical trials is permitted;\n21. Any condition that, in the opinion of the Investigator, may result in risk in the receipt of the study drug or that would interfere with the evaluation of the safety of the study drug or the interpretation of the study results. In the judgment of the Investigator, it is unlikely that Patients who, in the judgment of the Investigator, are less likely to comply with the study steps, restrictions, and requirements shall not be permitted to participate in this study.","75 Years",{"count":320,"type":22},39,[199],"Exploring the therapeutic effect of neoadjuvant chemotherapy combined with PD-1 inhibitor camrelizumab on advanced stage III-IV endometrial cancer",[324],"Endometrioid Endometrial Cancer",[326,327],"Neoadjuvant chemotherapy","PD-1 inhibitor (Camrelizumab)","2025-11-22",{"date":330,"type":38},"2025-12-01",{"date":332,"type":38},"2025-09-01",{"date":334,"type":22},"2031-12-01",{"name":44,"class":45},{"id":337,"slug":338,"hasResults":12,"nctId":339,"briefTitle":340,"officialTitle":341,"acronym":4,"eligibilityCriteria":342,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":343,"targetDuration":4,"studyType":23,"phases":345,"briefSummary":346,"conditions":347,"keywords":349,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":358,"leadSponsor":360,"locationsCount":46},"100611775","phase-2-neoadjuvant-ivonescimab-plus-chemotherapy-followed-by-concurrent-chemoradiotherapy-in-high-risk-locally-advanced-cervical-cancer-100611775","NCT07244965","Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer","Neoadjuvant Ivonescimab Combined With Paclitaxel and Cisplatin, Followed by Concurrent Chemoradiotherapy in Patients With High-Risk Locally Advanced Cervical Cancer：A Phase II, Single-Arm Study","Inclusion Criteria:\n\n* Able to understand and voluntarily sign the written informed consent form before any study-specific procedures.\n* Female participants aged ≥18 years on the day of signing informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Expected survival time ≥3 months.\n* Histologically confirmed diagnosis of cervical cancer.\n* Histological types limited to squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma.\n* No prior anti-tumor treatments (including but not limited to radiotherapy, chemotherapy, surgery, targeted therapy, and immunotherapy). Note: Lymph node dissection or biopsy for clinical staging is allowed.\n* FIGO 2018 stage III-IVA cervical cancer unsuitable for curative surgery. Lymph node metastasis may be confirmed by biopsy or imaging. Imaging-based lymph node metastasis must meet: MRI\u002FCT showing positive lymph node with short-axis diameter ≥10 mm, and ≥15 mm to be used as target lesion.\n* At least one measurable lesion per RECIST v1.1 criteria.\n* PD-L1 CPS score ≥1 in tumor tissue.\n* Must provide tumor tissue sample before treatment (FFPE blocks or ≥5 unstained slides, preferably freshly obtained).\n* Adequate organ function as per screening labs:\n* Hematological (without transfusion or growth factors within 2 weeks):\n* ANC ≥1.5×10⁹\u002FL\n* Platelets ≥90×10⁹\u002FL\n* Hemoglobin ≥9.0 g\u002FdL\n* Renal:\n* Creatinine ≤1.5×ULN or CrCl ≥50 mL\u002Fmin (≥60 mL\u002Fmin if cisplatin is planned), calculated by Cockcroft-Gault:\n\nCrCl (mL\u002Fmin) = \\[(140 - age) × weight (kg) × 0.85\\] \u002F \\[serum creatinine (mg\u002FdL) × 72\\]\n\n* Hepatic:\n* Total bilirubin ≤1.5×ULN (≤3×ULN if Gilbert's syndrome suspected)\n* AST and ALT ≤2.5×ULN\n* Coagulation:\n* INR ≤1.5×ULN and APTT ≤1.5×ULN (unless on anticoagulants with stable dosing)\n* Women of childbearing potential must have a negative serum pregnancy test within 7 days prior to first dose, and agree to use effective contraception during treatment and for at least 120 days after last dose of study drug and 180 days after chemoradiotherapy.\n* Effective contraception includes hormonal contraception, IUDs, or double barrier methods. Periodic abstinence and rhythm methods are not acceptable.\n\nExclusion Criteria:\n\n* Cervical cancer of non-eligible histology (e.g., neuroendocrine carcinoma, sarcoma).\n* Evidence of distant metastasis, including inguinal lymph node metastasis or lymph node involvement above L1 vertebral level.\n* History of total hysterectomy (removal of uterus and cervix). Subtotal hysterectomy or cornuostomy preserving the cervix is acceptable.\n* Anatomical or geometric contraindications to brachytherapy.\n* Active malignancies within 2 years, except for treated non-melanoma skin cancer, superficial bladder cancer, in-situ breast cancer (note: cervical carcinoma in situ history is exclusionary).\n* Bilateral hydronephrosis deemed non-relievable by nephrostomy or ureteral stenting.\n* Anti-tumor therapy within 2 weeks before treatment initiation (including but not limited to radiotherapy, chemotherapy, surgery, targeted therapy, immunotherapy, or immuno-co-stimulatory agents like ICOS, CD40, CD137, GITR, OX40 antibodies).\n* Immunomodulatory drugs (e.g., thymosin, interferon, IL-2) within 2 weeks before treatment.\n* Systemic corticosteroids (\\>10 mg\u002Fday prednisone or equivalent) or other immunosuppressants within 2 weeks, except:\n* Inhaled, ophthalmic, or topical steroids ≤10 mg\u002Fday prednisone or equivalent\n* Physiologic hormone replacement ≤10 mg\u002Fday prednisone or equivalent\n* Prophylactic corticosteroids for hypersensitivity (e.g., CT contrast)\n* Active infections requiring systemic treatment (e.g., active TB, syphilis, systemic fungal infections), except HBV antiviral therapy.\n* Severe infection within 4 weeks prior to treatment (e.g., hospitalization, sepsis, severe pneumonia).\n* Major surgery or significant trauma (e.g., fractures) within 4 weeks, or planned elective major surgery. Pelvic\u002Fpara-aortic lymph node dissection not exclusionary.\n* Live vaccines within 4 weeks.\n* Active or history of autoimmune diseases except for:\n* Vitiligo, alopecia, psoriasis, or eczema not requiring systemic therapy\n* Autoimmune thyroiditis requiring only stable hormone therapy\n* Type I diabetes requiring only stable insulin replacement\n* Any of the following cardiovascular\u002Fcerebrovascular diseases:\n* MI, unstable angina, PE, aortic dissection, DVT, or arterial embolism within 6 months\n* NYHA Class II or greater heart failure\n* Significant arrhythmias needing long-term treatment (stable asymptomatic Afib allowed)\n* Stroke (CVA) within 6 months\n* LVEF \\\u003C50%\n* History of myocarditis or cardiomyopathy\n* Known primary or secondary immunodeficiency, including HIV antibody positivity.\n* Active HBV infection: HBsAg positive with HBV DNA \\>1000 IU\u002FmL or \\>5000 copies\u002FmL; active HCV infection.\n* Exception: treated and stable HBV patients with HBV DNA ≤500 IU\u002FmL (or ≤2500 copies\u002FmL); cured HCV patients (HCVAb+ but HCV RNA-) allowed.\n* History of or active inflammatory bowel disease (Crohn's, ulcerative colitis), diverticulitis.\n* Known history of allogeneic organ or stem cell transplantation.\n* Interstitial lung disease or history of non-infectious pneumonitis.\n* History of severe hypersensitivity to monoclonal antibodies.\n* Known contraindications to cisplatin\u002Fcarboplatin or paclitaxel.\n* Pregnant or breastfeeding women.\n* Any condition that may interfere with the study drug's safety or efficacy evaluation as judged by the investigator (e.g., other serious illness, psychiatric disorders).",{"count":344,"type":22},42,[199],"This is a single-arm, phase II clinical trial evaluating the efficacy and safety of neoadjuvant Ivonescimab combined with paclitaxel and cisplatin (TP regimen), followed by concurrent chemoradiotherapy, in patients with high-risk, locally advanced cervical cancer (FIGO stage III-IVA). Eligible participants will receive two cycles of neoadjuvant Ivonescimab plus TP chemotherapy, followed by standard concurrent chemoradiotherapy. The primary endpoints include progression-free survival (PFS) and objective response rate (ORR) following neoadjuvant treatment. Secondary endpoints include overall survival (OS), disease control rate (DCR), safety, and quality of life (EORTC QLQ-C30). Exploratory analysis will focus on identifying predictive biomarkers for Ivonescimab efficacy.",[348],"LOCALLY ADVANCED CERVICAL CANCERS",[350,301,351,352,353],"Ivonescimab","Neoadjuvant","Immune Checkpoint Inhibitor","Concurrent Chemoradiotherapy","2025-11-20",{"date":356,"type":38},"2025-11-24",{"date":330,"type":22},{"date":359,"type":22},"2029-07-01",{"name":44,"class":45},{"id":362,"slug":363,"hasResults":12,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":368,"enrollmentInfo":369,"targetDuration":4,"studyType":23,"phases":371,"briefSummary":373,"conditions":374,"keywords":376,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":46},"100558075","phase-1-study-on-the-effect-of-combined-estrogen-and-progestogen-therapy-on-endometrial-repair-after-induced-abortion-100558075","NCT06546397","Study on the Effect of Combined Estrogen and Progestogen Therapy on Endometrial Repair After Induced Abortion","Prospective Cohort Study on the Effect of Combined Estrogen and Progestogen Therapy on Endometrial Repair and Ovarian Function Recovery After Induced Abortion","Inclusion Criteria:\n\n* Age between 18 years old (inclusive) and 40 years old (inclusive)\n* Body Mass Index (BMI) ranging from 18.5Kg\u002F㎡ to 23.9Kg\u002F㎡\n* Experienced at least 2 abortions or had a missed abortion\n* Confirmed gestational age of no more than 10 weeks, and the ultrasonic examination within three days prior to the surgery shows a gestational sac (average of three diameters) of at least 1.0cm, with an embryo length of no more than 3.0cm\n* Normal preoperative examination results as per the \"Clinical Diagnosis and Treatment Guidelines and Technical Operation Standards: Family Planning Volume (2017 Revision)\"\n* Capable of regular follow-ups and willing to sign the informed consent form.\n\nExclusion Criteria:\n\n* Individuals with contraindications to estrogen and progesterone therapy\n* History of uterine adhesions confirmed by hysteroscopy, or a history of uterine cavity surgery or uterine malformation correction\n* Subjects who require placement of an intrauterine device or administration of oral contraceptives or subcutaneous implants after the procedure\n* Individuals with mental status or cognitive function abnormalities who are unable to cooperate with the treatment process\n* Subjects who, in the opinion of the investigator, have potential risks or any other factors that may interfere with the study.","40 Years",{"count":370,"type":22},200,[372],"PHASE1","Induced abortion is a common method to terminate pregnancy, but during the operation, it is necessary to dilate the cervix and aspirate the uterine cavity. Repeated induced abortions may increase the risk of uterine damage, leading to cervical stenosis or intrauterine adhesions, thinning of the endometrium, which may affect the implantation of fertilized eggs and the development of embryos, and ultimately may lead to infertility or miscarriage. This study aims to explore the effects of combined estrogen and progesterone on endometrial repair and ovarian function recovery after induced abortion.",[375],"Pregnancy Complications",[377,378,379,380],"induced abortion","Intrauterine adhesion","estrogen","endometrial repair","2025-08-20",{"date":383,"type":38},"2025-08-28",{"date":385,"type":38},"2024-05-09",{"date":387,"type":22},"2025-12-31",{"name":44,"class":45},{"id":390,"slug":391,"hasResults":12,"nctId":392,"briefTitle":393,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":395,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":399,"lastUpdatePostDateStruct":400,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":4},"100601158","prenatal-cell-free-dna-screening-in-pregnancies-with-diverse-genetic-risk-profiles-utilizing-targeted-and-whole-exome-sequencing-100601158","NCT07106853","Prenatal Cell-free DNA Screening in Pregnancies With Diverse Genetic Risk Profiles Utilizing Targeted and Whole-exome Sequencing","Inclusion Criteria:\n\n* Adult pregnant woman (≥18 years old)\n* Gestational age between 9+0 and 25+6 weeks\n* Singleton pregnancy\n* Pregnancy with indications for prenatal diagnosis due to:\n\n  * Increased nuchal translucency (NT) ≥3.5 mm: capped at 25% of total subjects\n  * Increased NT ≥3.5 mm AND presence of any other \"soft marker\" or structural anomaly: capped at 25% of total subjects\n  * Presence of structural anomaly: at least 50% of total subjects\n* Agree to participate in the clinical study for being followed-up and accept at least one molecular diagnosis (diagnostic procedures performed on prenatal invasive specimens, product of conception, umbilical cord blood, or other specimens) and possible family member testing\n\nExclusion Criteria:\n\n* Age under 18 years\n* Gestational age is less than 9+0 weeks or greater than 25+6 weeks\n* One parent or other family member has a known pathogenic variant linked to the fetal ultrasound finding(s)\n* Conditions affecting the accuracy of cfDNA assay (e.g., maternal malignancy during pregnancy, maternal allogeneic blood transfusion, organ transplantation, or cell therapy within the past year)",{"count":396,"type":22},1600,"This multicenter study aims to recruit a minimum of 1,600 pregnant women, encompassing individuals with varying levels of genetic risk. The study particularly focuses on cases with increased fetal nuchal translucency (NT ≥3.5 mm), additional ultrasound markers, and\u002For fetal structural anomalies. Peripheral blood samples of eligible participants will be collected for two state-of-the-art cfDNA tests based on coordinative allele-aware target enrichment sequencing (COATE-seq): (1) a targeted panel to screen for frequent chromosomal aneuploidies, microdeletions\u002Fduplications, and dominant single-gene conditions, and (2) comprehensive whole-exome cfDNA sequencing for aneuploidies, microdeletions\u002Fduplications, monogenic variants (both dominant and recessive variants), uniparental disomy, and hydatidiform moles. The results of both cfDNA tests will be compared with those from invasive or postnatal diagnostic testing. Pregnancy outcome will be followed up to six weeks postpartum. The primary goal is to determine the clinical validity of targeted and whole exome cfDNA analyses, assessed through sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) relative to diagnostic standards. Secondary goal is to assess efficacy across diverse genetic risk populations by analyzing detection rates of pathogenic variants associated with fetal indications. The clinical utility of cfDNA screening will also be evaluated by its impact on clinical management decisions, including follow-up diagnostic procedures or prenatal\u002Fperinatal interventions.",[225],"2025-07-29",{"date":401,"type":38},"2025-08-06",{"date":403,"type":22},"2025-08-01",{"date":405,"type":22},"2027-05-31",{"name":44,"class":45},{"id":408,"slug":409,"hasResults":12,"nctId":410,"briefTitle":411,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":318,"enrollmentInfo":413,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":415,"conditions":416,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":419,"startDateStruct":421,"completionDateStruct":423,"leadSponsor":425,"locationsCount":46},"100517621","study-on-the-dynamic-changes-of-metabolic-biomarkers-and-their-prognostic-relationship-in-ovarian-cancer-100517621","NCT06019923","Study on the Dynamic Changes of Metabolic Biomarkers and Their Prognostic Relationship in Ovarian Cancer","Inclusion Criteria:\n\n* Age between 18 and 75 years;\n* Pathological diagnosis of high-grade serous ovarian cancer;\n* Newly diagnosed ovarian cancer case without prior neoadjuvant therapy.\n\nExclusion Criteria:\n\n* Non-primary (recurrent) patients;\n* Ovarian cancer patients who have not undergone surgical treatment;\n* Patients with a history of other malignancies.",{"count":414,"type":22},100,"Ovarian cancer is a highly lethal gynecological malignancy, often diagnosed at an advanced stage, with high rates of recurrence within 1-2 years after frontline treatment. Current guidelines recommend monitoring tumor markers CA125 and HE4 for disease progression, but these markers may not detect recurrence or disease progression when their levels are below the detection limit. Therefore, there is a need to identify new prognostic biomarkers and monitor their dynamic changes for effective risk stratification and personalized treatment in patients with ovarian cancer",[417],"Ovarian Cancer","2025-07-14",{"date":420,"type":38},"2025-07-17",{"date":422,"type":38},"2023-10-26",{"date":424,"type":22},"2027-09-10",{"name":44,"class":45},{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":17,"minAge":273,"maxAge":318,"enrollmentInfo":432,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":434,"conditions":435,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":418,"lastUpdatePostDateStruct":436,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":46},"100488054","a-cohort-study-of-uterine-malignancies-100488054","NCT05635123","A Cohort Study of Uterine Malignancies","Inclusion Criteria:\n\n* Age 20-75 years;\n* Women with cervical cancer or endometrial cancer with a definite pathological diagnosis for the first time;\n* Women attending a health check-up;\n* Obtain informed consent and sign an informed consent form.\n\nExclusion Criteria:\n\n* Patients who are unable to cooperate with the investigations such as mental disorders or cognitive impairment；\n* Patients with cancer other than cervical cancer or endometrial cancer;\n* Women who have received hysterectomy or pelvic radiation therapy previously.",{"count":433,"type":22},6200,"The purposes of current study were to explore the relationship between cervical cancer\u002Fendometrial cancer and demographic information, behavior and life style, pregnancy-related factors, and disease history, and to study the factors affecting the prognosis of cancers. In addition, omics tests were performed on the biological specimens to identify the diagnostic markers and prognostic biomarkers.",[301,202],{"date":420,"type":38},{"date":438,"type":38},"2023-09-15",{"date":440,"type":22},"2030-12-01",{"name":44,"class":45},{"id":443,"slug":444,"hasResults":12,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":448,"eligibilityCriteria":449,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":368,"enrollmentInfo":450,"targetDuration":4,"studyType":23,"phases":451,"briefSummary":452,"conditions":453,"keywords":455,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":468,"locationsCount":90},"100592887","phase-3-light-trial-levothyroxine-for-gestational-hypothyroidism-in-recurrent-pregnancy-loss-100592887","NCT06999278","LIGHT Trial: Levothyroxine for Gestational Hypothyroidism in Recurrent Pregnancy Loss","LIGHT - Levothyroxine for Isolated Gestational HypoThyroidism in Women With Recurrent Pregnancy Loss: a Multicenter Randomized, Double-blind, Placebo-controlled Trial - a Study Protocol","LIGHT","Inclusion Criteria:\n\n* women with singleton pregnancy\n* women with a history of recurrent pregnancy loss (defined as two or more pregnancy loss before 20wks)\n* women diagnosed with isolated maternal hypothyroidism (defined as isolated lower level of FT4 with normal TSH levels) in the current pregnancy before 20wks\n\nExclusion Criteria:\n\n* patients with known thyroid disorders\n* patients with antiphospholipid syndrome or other autoimmune conditions\n* patients with contraindications to levothyroxine (e.g., acute cardiac arrest, acute pancreatitis, acute myocarditis)\n* patients attending other ongoing clinical trials or unwilling to participate.",{"count":370,"type":22},[25],"The goal of this randomized, double-blind, placebo-controlled clinical trial is to evaluate whether levothyroxine supplement improves pregnancy outcomes in women with recurrent pregnancy loss (RPL) and isolated maternal hypothyroidism (IMH).\n\nThe main questions it aims to answer are:\n\nDoes levothyroxine increase the live birth rate after 24 weeks of gestation? Does levothyroxine improve secondary outcomes such as ongoing pregnancy rates, reduce the incidence of pregnancy loss, or influence maternal and neonatal complications?\n\nResearchers will:\n\nCompare the levothyroxine treatment group (50 µg\u002Fday) to the placebo group to assess the impact of the intervention on live birth rates and other pregnancy outcomes.\n\nParticipants will:\n\nBe randomly assigned to receive either levothyroxine or a placebo. Take the assigned treatment daily starting from enrollment until the end of pregnancy.\n\nUndergo routine follow-up visits to monitor pregnancy progress and outcomes. This trial seeks to determine whether routine levothyroxine supplementation can improve pregnancy outcomes for women with RPL and IMH.",[454],"Abortion, Habitual",[456,457,458,459,460,461],"recurrent pregnancy loss","isolated maternal hypothyroidism","levothyroxine","adverse pregnancy outcomes","live birth","neonatal complications","2025-05-31",{"date":464,"type":38},"2025-06-04",{"date":466,"type":22},"2025-06-01",{"date":405,"type":22},{"name":44,"class":45},{"id":470,"slug":471,"hasResults":12,"nctId":472,"briefTitle":473,"officialTitle":474,"acronym":4,"eligibilityCriteria":475,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":476,"enrollmentInfo":477,"targetDuration":4,"studyType":23,"phases":479,"briefSummary":480,"conditions":481,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":483,"lastUpdatePostDateStruct":484,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":46},"100588212","preventive-effect-of-probiotics-in-gdm-100588212","NCT06938464","Preventive Effect of Probiotics in GDM","The Preventive Effect of Probiotics in Pregnant Women With High-risk for Gestational Diabetes","Inclusion Criteria:\n\n* Pregnant women who meet the high-risk indicators for GDM and agree to participate in this study.\n\n  1. included between 12-16 gestational weeks\n  2. A woman was considered high risk when her pre-pregnancy BMI ≥ 24 kg\u002Fm\\^2, having family history of diabetes (type 1 or 2), GDM or PCOS (polycystic ovary syndrome) history, history of delivering macrosomia or stillbirth, or glucose in urine (+)\n\nExclusion Criteria:\n\n1. Taking probiotics or prebiotics within the past month\n2. Have a history of allergies to the drug components or similar drugs in this study\n3. Having long-term smoking or drinking habits\n4. Type 1 or type 2 diabetes patients with definite diagnosis before pregnancy\n5. Diseases in other important organs such as heart, liver, and kidney\n6. with clear digestive system diseases\n7. Multiple pregnancy\n8. with mental or cognitive impairments who are unable to complete this study","50 Years",{"count":478,"type":22},334,[152],"Gut microbiota is instrumental in the microbial and metabolic network of pregnant women, and is potentially related with gestational diabetes. Perinatal probiotic intervention contributes to improved glucose regulation during pregnancy. Our randomized, double-centered, placebo-controlled study is planned to recruit 334 pregnant women who is in high risk for gestational diabetes. They will be assumed randomly probiotic powder per day or placebo from 12-16th gestational weeks until Oral Glucose Tolerance Test (OGTT) at 24-28th gestational weeks. Perinatal outcomes about neonatal weight will be registered.",[482],"Gestational Diabetes Mellitus (GDM)","2025-04-23",{"date":485,"type":38},"2025-04-27",{"date":487,"type":38},"2023-10-27",{"date":489,"type":22},"2026-11-01",{"name":44,"class":45},{"id":492,"slug":493,"hasResults":12,"nctId":494,"briefTitle":495,"officialTitle":496,"acronym":497,"eligibilityCriteria":498,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":318,"enrollmentInfo":499,"targetDuration":4,"studyType":23,"phases":501,"briefSummary":502,"conditions":503,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":506,"lastUpdatePostDateStruct":507,"startDateStruct":509,"completionDateStruct":511,"leadSponsor":513,"locationsCount":514},"100453048","profiling-based-endometrial-cancer-adjuvant-therapy-100453048","NCT05179447","PROfiling Based Endometrial Cancer Adjuvant Therapy","Randomized Phase III Trial of Molecular Profile-based Versus Standard Recommendations for Adjuvant Therapy for Women With Early Stage Endometrioid Adenocarcinoma","PROBEAT","Inclusion Criteria:\n\n1. Surgery consisting of a total abdominal or laparoscopic hysterectomy, bilateral salpingectomy, pelvic lymphadenectomy or sentinel lymph node mapping and dissection, with or without para-aortic lymphadenectomy, oophorectomy\n2. Histologically confirmed endometrioid type endometrial carcinoma, International Federation of Gynecology and Obstetrics (FIGO) 2009 stage I, with one of the following combinations of stage and grade:\n\n   Stage I A, grade 3 Stage I B, grade 1 or 2 Stage I B, grade 3 Stage II\n3. World Health Organization (WHO)-performance status 0-2\n4. Written informed consent\n\nExclusion Criteria:\n\n1. With residual disease\n2. Any other stage and type of endometrial carcinoma\n3. Histological types serous carcinoma or clear cell carcinoma (at least 10% if mixed type), or undifferentiated or neuroendocrine carcinoma\n4. Uterine sarcoma (including carcinosarcoma)\n5. Previous malignancy (except for non-melanomatous skin cancer)\n6. Previous pelvic radiotherapy\n7. Expected interval between the operation and start of radiotherapy exceeding 8 weeks",{"count":500,"type":22},590,[152],"This is a prospective, multicenter, randomized phase III trial among women with endometrioid adenocarcinoma with high-intermediate and intermediate risk features to investigate the role of integrated genomic-pathologic classification to determine if participants should receive no adjuvant therapy, vaginal brachytherapy, external beam radiotherapy or chemo-radiation therapy based on molecular features as compared to standard radiation therapy.",[504,505],"Endometrial Cancer Stage I","Endometrial Cancer Stage II","2025-03-26",{"date":508,"type":38},"2025-04-01",{"date":510,"type":38},"2022-01-24",{"date":512,"type":22},"2027-01-01",{"name":44,"class":45},10,{"id":516,"slug":517,"hasResults":12,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":76,"enrollmentInfo":522,"targetDuration":4,"studyType":23,"phases":524,"briefSummary":525,"conditions":526,"keywords":4,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":535,"locationsCount":4},"100582995","phase-3-comparative-study-of-adjuvant-therapy-for-postoperative-cervical-gastric-type-adenocarcinoma-100582995","NCT06870565","Comparative Study of Adjuvant Therapy for Postoperative Cervical Gastric-type Adenocarcinoma","A Multicenter Randomized Study Comparing Paclitaxel and Platinum-based Concurrent Chemoradiotherapy With Short-term Adjuvant Chemotherapy Versus Platinum-based Monotherapy Concurrent Chemoradiotherapy in Patients With Postoperative Cervical Gastric-type Adenocarcinoma With High-risk Factors for Recurrence.","Inclusion Criteria:\n\n1. Pathologically confirmed Gastric-type endocervical adenocarcinoma;\n2. Based on standard examination procedures, it is determined that one of the following risk factors is combined: positive margin, positive paracervical involvement, adnexal involvement, positive lymph nodes, tumor diameter ≥ 4cm, infiltration of the outer 1\u002F3 of the cervical stroma, and vascular tumor thrombus. The specific inclusion can be discussed by two senior clinical doctors;\n3. Medical history inquiry and gynecological examination must be performed within 14 days before enrollment to confirm the size of the tumor and International Federation of Gynecology and Obstetrics (FIGO) stage;\n4. Chest Computed Tomography (CT) plain scan, abdominal enhanced CT scan, or Positron Emission Tomography (PET)\u002FCT examination within 30 days before enrollment;\n5. Pelvic CT, Magnetic Resonance Imaging (MRI) or PET\u002FCT examination within 30 days before enrollment;\n6. General condition score 0-1 points;\n7. Age 18-65 years old;\n8. Laboratory examinations must be performed within 14 days before enrollment, and bone marrow, liver function, and kidney function tests are performed:\n\n   1. White blood cell (WBC) ≥ 3.5 x 10E9\u002FL (normal range)\n   2. Neutrophils ≥ 1.5 x 10E9\u002FL;\n   3. Platelets ≥ 100 x 10E9\u002FL;\n   4. Hemoglobin ≥ 100 g\u002FL (transfusion or other methods are acceptable)\n   5. Liver function is within the normal range: alanine aminotransferase (ALT), aspartate aminotransferase (AST) \\\u003C 1.5 times the upper limit of normal, alkaline phosphatase (ALP) \\\u003C 2.5 times the upper limit of normal, bilirubin \\\u003C upper limit of normal.\n   6. Renal function is within the normal range: creatinine clearance rate (CCr) \\> 60 ml\u002Fmin.\n\nCalculation formula: CCr=(140-age)×weight (kg)\u002F\\[72×Scr (mg\u002Fdl)\\] or CCr=\\[(140-age)×weight (kg)\\]\u002F\\[0.818×Scr (umol\u002FL)\\] g) International prothrombin ratio (INR) ≤ 1.5 9. Women of childbearing age must agree to take effective contraceptive measures during the entire treatment study; 10. Patients must sign an informed consent form before enrollment;\n\nExclusion Criteria:\n\n1. Pathological types of non-gastric adenocarcinomas such as squamous cell carcinoma, adenosquamous carcinoma, undifferentiated carcinoma, small cell carcinoma, neuroendocrine carcinoma, and sarcoma of cervical cancer;\n2. Stage IVB;\n3. Previous invasive malignant tumors: excluding non-malignant melanoma skin cancer;\n4. Systemic chemotherapy in the past 3 years;\n5. Previous history of pelvic or abdominal radiotherapy, which may cause overlap of irradiation field for this radiotherapy;\n6. Distant metastatic lesions in other organs;\n7. The following serious active concurrent diseases:\n\n1\\) Unstable angina and\u002For congestive heart failure requiring hospitalization in the past 6 months 2) Transmural myocardial infarction in the past 6 months 3) Acute bacterial or fungal infection requiring intravenous antibiotic treatment at the time of registration 4) Exacerbation of chronic obstructive pulmonary disease or other respiratory diseases requiring hospitalization or hindering the study 5) Jaundice or coagulation disorder caused by poor liver function 6) Acquired immunodeficiency disease (Patients diagnosed with Acquired Immune Deficiency Syndrome (AIDS), or patients suspected of having AIDS who refuse HIV testing); 7) Other immunocompromised states (e.g. organ transplantation, long-term use of glucocorticoids); 8. Pregnant women, breastfeeding women.",{"count":523,"type":22},238,[25],"Background: Gastric-type endocervical adenocarcinoma (G-EAC) is a new classification of cervical mucinous carcinoma. G-EAC is a unique human papillomavirus unrelated adenocarcinoma that can be distinguished from typical endocervical adenocarcinoma (UEA). In China, adjuvant therapy for cervical cancer after surgery includes not only radiotherapy (RT) or concurrent chemoradiotherapy (CCRT), but also chemotherapy in many cases. However, no previous prospective study has analyzed the adjuvant therapy of G-EAC. This study is the first randomized phase III trial, which aims to recommend better adjuvant treatment options for G-EAC patients at high risk of recurrence in China, in order to better optimize and personalize patient care and improve recurrence-free survival and overall survival.\n\nMethods: This trial is a prospective, multicenter study led by the Department of Radiotherapy, Affiliated Hospital of Obstetrics and Gynecology, Zhejiang University. Recruitment will begin in February 2025, and it is expected that 238 patients with postoperative cervical gastric adenocarcinoma with high risk of recurrence will be recruited from 16 clinical centers in China. Patients will be randomly assigned to the experimental group or the control group in a 1:1 ratio. The experimental group will receive paclitaxel combined with platinum-based concurrent chemoradiotherapy and short-term adjuvant chemotherapy, and the control group will receive the current standard treatment regimen, i.e., platinum-based concurrent chemoradiotherapy, without adjuvant chemotherapy. The primary endpoint of the study is the 2-year progression-free survival, and the secondary endpoints are disease treatment failure pattern, overall survival rate, acute\u002Fchronic toxicity incidence, and quality of life assessment.",[527,301],"Gastric-type Endocervical Adenocarcinoma","2025-03-13",{"date":530,"type":38},"2025-03-17",{"date":532,"type":22},"2025-03",{"date":534,"type":22},"2030-12",{"name":44,"class":45},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":541,"acronym":4,"eligibilityCriteria":542,"healthyVolunteers":12,"sex":17,"minAge":53,"maxAge":318,"enrollmentInfo":543,"targetDuration":4,"studyType":23,"phases":545,"briefSummary":546,"conditions":547,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":559,"leadSponsor":560,"locationsCount":561},"100495907","phase-3-nab-paclitaxel-versus-sb-taxanes-as-first-line-treatment-in-advanced-ovarian-cancer-100495907","NCT05737303","Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer","Nab-paclitaxel Versus Solvent-based Taxanes As First-Line Treatment for Patients With Advanced Ovarian Cancer","Inclusion Criteria:\n\n1. Epithelial ovarian cancer\u002Ftubal cancer\u002Fperitoneal cancer was diagnosed by histopathology or hydroexfoliation cytopathology of the chest and abdomen, and was classified as stage III-IV according to FIGO（International Federation of Gynecology and Obstetrics）stage\n2. Physical condition Eastern Cooperative Oncology Group PS score: 0-2 points\n3. Participants who had not participated in other drug clinical trials within 4 weeks prior to enrollment\n4. Written informed consent\n5. Expected survival ≥6 months\n6. The disease met the criteria for Efficacy Evaluation of solid tumors (RECIST 1.1)\n7. Be able to comply with outpatient treatment, laboratory monitoring, and necessary clinical visits during study participation.\n\nExclusion Criteria:\n\n1. Patients with low malignant potential ovarian tumors;\n2. Other malignant tumors within the previous 5 years, except for cured cervical carcinoma in situ and non-melanoma skin cancer;\n3. Patients who have previously received chemotherapy or radiotherapy for pelvic cavity;\n4. Patients with central nervous system metastasis or peripheral neuropathy \\> grade 1;\n5. Patients with severe myelosuppression, severe liver dysfunction (Child's Class III), or renal dysfunction at the time of screening;\n6. Severe cardiovascular disease: Grade Ⅱ or above myocardial ischemia or myocardial infarction, poorly controlled arrhythmias (including QTc interval ≥470 ms); According to NYHA（New York Heart Association） criteria, patients with grade Ⅲ to Ⅳ cardiac insufficiency or left ventricular ejection fraction (LVEF) \\\u003C 55% indicated by color Doppler ultrasonography;\n7. Uncontrolled systemic infection requiring anti-infective treatment;\n8. Arteriovenous thrombosis events occurring within 6 months before randomization, such as cardiovascular and cerebrovascular accidents (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction, myocardial infarction), deep vein thrombosis and pulmonary embolism;\n9. Patients who are allergic to the active ingredients or excipients of albumin paclitaxel and carboplatin for injection;\n10. Pregnant or lactating women;\n11. Those who were considered unsuitable for inclusion by the researchers.",{"count":544,"type":22},538,[25],"The purpose of this study is to compare the efficacy and safety of nab-paclitaxel with solvent-based taxanes as first-line treatment for patients with advanced primary epithelial ovarian cancer (EOC), primary peritoneal carcinoma or fallopian tube carcinoma.",[548,549,550,551,552,553],"Epithelial Ovarian Carcinoma Stage III","Epithelial Ovarian Carcinoma Stage IV","Fallopian Tube Carcinoma Stage III","Fallopian Tube Carcinoma Stage IV","Primary Peritoneal Carcinoma Stage III","Primary Peritoneal Carcinoma Stage IV","2025-02-09",{"date":556,"type":38},"2025-02-11",{"date":558,"type":38},"2023-11-27",{"date":264,"type":22},{"name":44,"class":45},11,{"id":563,"slug":564,"hasResults":12,"nctId":565,"briefTitle":566,"officialTitle":567,"acronym":4,"eligibilityCriteria":568,"healthyVolunteers":12,"sex":220,"minAge":4,"maxAge":569,"enrollmentInfo":570,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":572,"conditions":573,"keywords":575,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":579,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":584,"locationsCount":46},"100503964","clinical-value-of-etcoc-in-the-diagnosis-and-treatment-of-abo-hdn-100503964","NCT05842109","Clinical Value of ETCOc in the Diagnosis and Treatment of ABO-HDN","Clinical Value of ETCOc in the Diagnosis and Treatment of ABO Hemolytic Disease of the Newborn","Inclusion Criteria:\n\n* gestational age between 35+0 and 41+6 weeks\n* birth weight ≥ 2500 grams\n* respiratory rate \\\u003C 60 breaths per minute\n* the neonates admitted to the neonatology department for phototherapy because of hyperbilirubinemia that conforms to the guideline of the experts consensus on the management of neonatal hyperbilirubinemia(2014,in China.)\n* ABO group incompatibility between the mother and newborn\n* the informed consent are obtained.\n\nExclusion Criteria:\n\n* persistent dyspnea or need for respiratory support\n* skin damage or structural deformity around the nasal cavity\n* receive intensive care treatment in the neonatal intensive care unit(NICU)\n* Severe congenital malformation, chromosomal or genetic abnormality","7 Days",{"count":571,"type":22},112,"A prospective observational cohort study was designed.\n\n1. Comparing of the clinical indicators between the hemolytic group and the non-hemolytic group,such as End-tidal carbon monoxide corrected for ambient CO(ETCOc),direct antiglobulin test(DAT), the highest total serum bilirubin level and hemoglobin. To explore the role of ETCOc in the diagnosis of neonatal ABO hemolytic disease.\n2. Comparing of the clinical indicators between the neonates with IVIG treatment and the neonates without IVIG treatment in ABO hemolytic disease, such as ETCOc,total serum bilirubin level before IVIG treatment and ETCOc,total serum bilirubin level after IVIG treatment.To explore the clinical value of ETCOc in the treatment of ABO hemolytic disease.",[574],"ABO Hemolytic Disease of Newborn",[576,577,574],"End tidal carbon monoxide","hyperbilirubinemia","2025-01-31",{"date":580,"type":38},"2025-02-05",{"date":582,"type":38},"2023-10-31",{"date":42,"type":22},{"name":44,"class":45},{"id":586,"slug":587,"hasResults":12,"nctId":588,"briefTitle":589,"officialTitle":590,"acronym":4,"eligibilityCriteria":591,"healthyVolunteers":12,"sex":17,"minAge":592,"maxAge":593,"enrollmentInfo":594,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":596,"conditions":597,"keywords":600,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":606,"lastUpdatePostDateStruct":607,"startDateStruct":609,"completionDateStruct":611,"leadSponsor":613,"locationsCount":46},"100570931","predicting-treatment-failure-in-hsil-patients-with-positive-margins-after-conization-via-detection-of-pax1-methylation-100570931","NCT06713655","Predicting Treatment Failure in HSIL Patients with Positive Margins After Conization Via Detection of PAX1 Methylation","Multicenter Study on PAX1 Methylation for Predicting Lesion Persistence\u002FRecurrence in HSIL Patients with Positive Margins After Cervical Conization","Inclusion Criteria:\n\n* Age greater than 25 years and less than 55 years;\n* First-time cervical conization (cold knife conization or loop electrosurgical excision procedure);\n* Postoperative pathology showing HSIL (CIN2 or CIN3);\n* Positive margins for HSIL (CIN2 or CIN3) in conization specimen.\n\nExclusion Criteria:\n\n* The presence of other malignant tumors or precancerous lesions;\n* Lack of willingness for follow-up;\n* Pregnant or breastfeeding women;\n* Unable or unwilling to complete follow-up examinations;\n* History of prior cervical disease treatment (surgical or physical therapy);\n* Presence of immune system disorders.","26 Years","54 Years",{"count":595,"type":22},800,"The goal of this multicenter, observational study is to evaluate whether methylation testing of paired box gene 1 (PAX1) can better predict and diagnose recurrence or persistent disease in patients with positive margins after cervical conization for high-grade squamous intraepithelial lesion (HSIL). The main question it aims to answer is:\n\nCan PAX1 gene methylation testing provide a more accurate and effective prediction and diagnosis of cervical disease recurrence\u002Fpersistence in addition to existing methods? Participants will be managed according to the latest clinical guidelines, and during follow-up, a non-invasive test, PAX1 gene methylation testing, will be added.",[598,599],"High-grade Squamous Intraepithelial Lesions (HSIL)","Cervical Conization",[601,602,603,128,604,605],"cervical intraepithelial neoplasia","conization","positive margins","treatment failure","residual\u002Frecurrent disease","2024-12-03",{"date":608,"type":38},"2024-12-06",{"date":610,"type":22},"2024-12",{"date":612,"type":22},"2028-07",{"name":44,"class":45},""]